: Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear
factor-kappaB Pathway. Am J Pathol 2010,176(2):699–709.PubMedCrossRef 14. Dupasquier S, Abdel-Samad R, Glazer RI, Bastide P, Jay P, Joubert D, Cavailles V, Blache P, Quittau-Prevostel C: A new mechanism of SOX9 action to regulate PKCalpha expression in the intestine epithelium. J Cell Sci 2009,122(Pt 13):2191–2196.PubMedCrossRef 15. Darido C, Buchert M, Pannequin J, Bastide P, Zalzali H, Mantamadiotis T, Bourgaux JF, Garambois V, Jay P, Blache P, et al.: Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. Cancer Res 2008,68(11):4258–4268.PubMedCrossRef 16. Okubo T, Knoepfler PS, Eisenman RN, Hogan BL: Nmyc plays
an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation ACP-196 concentration and differentiation. Development selleck compound 2005,132(6):1363–1374.PubMedCrossRef 17. Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, Berney DM, Moller H, Reuter VE, Scardino P, et al.: SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 2010,70(3):979–987.PubMedCrossRef 18. Carbonnelle-Puscian A, Vidal V, Laurendeau I, Valeyrie-Allanore L, Vidaud D, Bieche I, Leroy K, Lantieri L, Wolkenstein P, Schedl A, et al.: SOX9 expression increases with malignant
potential CHIR-99021 nmr in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog. Hum Pathol 2011,42(3):434–443.PubMedCrossRef 19. Ling S, Chang X, Schultz L, Lee TK, Chaux A, Marchionni L, Netto GJ, Sidransky D, Berman DM: An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res 2011,71(11):3812–3821.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions Chun-Hui Zhou and Li-Ping Ye participated in the data collection, performed the statistical analysis and drafted the manuscript. Shi-Xing Ye assisted with the data collection, Yan-Li, Xin-Yin Zhang, Xin-Yu Xu made substantial contributions to the analysis and interpretation of data, Dr. Li-Yun Gong conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.”
“Background Immunoglobulin (Ig)D multiple myeloma (IgD MM) is a rare subtype of myeloma, accounts for less than 2% of all myelomas [1] and is accompanied with aggressive course, resistance to chemotherapy and poor outcome. It is often associated with relatively high frequencies of renal failure, extra osseous disease, hypercalcemia, amyloidosis and Bence-Jones proteinuria [2–5]. The survival of patients with IgD MM has been reported to be shorter than that of patients with other types of M-protein [2, 4, 6].